
ReciBioPharm Expands Oxford Collaboration to Advance Two Malaria Vaccines
ReciBioPharm, the advanced biologics division of Recipharm and a leading CDMO, has extended its long-standing partnership with the University of Oxford to support the clinical development of two malaria vaccine candidates, R78C and RH5.1. The collaboration builds on a relationship